Merck & Co., Inc.

MRK - CIK 0000310158

Market cap$293.16 B

Rank#44

SEC filings996

Merck & Co., Inc. trades as MRK and has a market capitalization of $293.16 B, making it the #44 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $65.01B, up 1.3% from the prior year and net income of $18.25B. This page tracks Merck & Co., Inc. through 996 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$65.01BFY 2025

Net income (latest FY)$18.25BFY 2025

Operating cash flow (latest FY)$16.47BFY 2025

Total assets (latest FY)$136.87BFY 2025

Net margin28.1%latest FY

Financial performance

Over the last 9 fiscal years Merck & Co., Inc.'s revenue grew from $39.81B to $65.01B, a compound annual growth rate of 5.6%. Net profit margin expanded from 9.8% to 28.1% over the same period - every figure below comes from the company's audited annual filings.

MRK annual revenueView details

Key statistics

Market cap: $293.16 B
Share price (derived)market cap / shares outstanding: $118.69
P/E ratio (trailing FY): 16.1
EPS (diluted)FY 2025: $7.28
Shares outstandingas of 2026-04-30: 2.47B
Total equityas of 2026-03-31: $45.88B
Return on equity: 39.8%
Long-term debtas of 2026-03-31: $46.67B

Latest filings

Filing	Type	Filed
Prospectus supplement	424B5	2026-05-20
Free writing prospectus	FWP	2026-05-19
Prospectus supplement	424B5	2026-05-18
Institutional holdings	13F-HR	2026-05-13
Insider trade	4	2026-05-07
Insider trade	4	2026-05-07
Insider trade	4	2026-05-07
Insider trade	4	2026-05-07

Browse the full filing history (996 filings)

Recent press releases

Impact Report2026-05-18
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Merck.com
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 20262026-05-07
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate2026-05-05
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.2026-04-30
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.2026-04-22
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

Similar companies

The largest companies sharing Merck & Co., Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T MRK vs LLY

JNJJohnson & Johnson$573.98 B MRK vs JNJ

ABBVAbbVie Inc.$399.47 B MRK vs ABBV

AZNAstraZeneca PLC$286.27 B MRK vs AZN

NVSNovartis AG$283.13 B MRK vs NVS

GSK

Frequently asked questions

What is Merck & Co., Inc.'s market cap?

Merck & Co., Inc. (MRK) has a market capitalization of $293.16 B as of 2026-06-10, ranking #44 among US-listed companies.

How much revenue does Merck & Co., Inc. make?

Merck & Co., Inc. reported revenue of $65.01B for fiscal year 2025, an increase of 1.3% year over year.

Is Merck & Co., Inc. profitable?

Yes. Merck & Co., Inc. reported net income of $18.25B in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.